Non-Hodgkin Lymphoma
Non-Hodgkin Lymphoma (NHL)
Non-Hodgkin Lymphoma (NHL) is a diverse group of blood cancers that start in the lymphocytes (white blood cells). Unlike Hodgkin Lymphoma, NHL is much more common and behaves in a less predictable way, often appearing in multiple lymph node groups simultaneously.
When You Should Consider Non-Hodgkin Lymphoma Evaluation
Painless swelling of lymph nodes in the neck, armpit, or groin.
Drenching night sweats.
Unexplained fever and persistent fatigue.
Sudden weight loss of more than 10% of body weight.
Abdominal pain or swelling, which may indicate liver or spleen involvement.
Methods of Non-Hodgkin Lymphoma Classification
Indolent (Low-grade): Slow-growing types like Follicular Lymphoma that are manageable over many years.
Aggressive (High-grade): Fast-growing types like Diffuse Large B-cell Lymphoma (DLBCL) that require immediate intensive treatment.
B-cell Lymphomas: The most common category, accounting for approximately 85% of all cases.
T-cell Lymphomas: A less common category, making up about 15% of cases.
How Non-Hodgkin Lymphoma Is Managed
R-CHOP Chemotherapy: The standard regimen for aggressive B-cell lymphomas, combining traditional chemotherapy with the antibody Rituximab.
Immunotherapy: Use of bispecific antibodies like Polatuzumab or Mosunetuzumab to help the immune system target cancer cells.
CAR T-cell Therapy: A revolutionary approach for relapsed cases involving the genetic re-engineering of a patient's own T-cells.
Watch and Wait: Active surveillance used for slow-growing indolent types to monitor the disease before starting intervention.
Targeted Therapy: Specialized drugs tailored to the specific genetic makeup of the lymphoma subtype.
Pre-Procedure Preparation
Determining the growth rate (indolent vs. aggressive) to establish the necessary speed of treatment.
Preparing for a surgical biopsy to ensure a large enough tissue sample for accurate subtyping.
Baseline cardiac and organ function testing to ensure the patient can tolerate intensive R-CHOP regimens.
For CAR T-cell therapy, undergoing a process to collect T-cells from the blood for laboratory modification.
Tests Before Non-Hodgkin Lymphoma Treatment
Excisional Biopsy: The removal of an entire lymph node to definitively identify the specific NHL subtype.
PET/CT Scan: Advanced imaging to determine the stage (I to IV) based on the location of the cancer relative to the diaphragm.
Bone Marrow Biopsy: A procedure to check if the lymphoma has spread to the body's blood-producing marrow.
Molecular Profiling: Testing the cancer cells for specific proteins or genetic markers to guide immunotherapy choices.
Life After Non-Hodgkin Lymphoma Treatment
The overall 5-year survival rate for NHL is approximately 74%, though this varies by subtype.
Many patients with aggressive types achieve a total cure if they respond well to initial intensive therapy.
Indolent lymphoma patients may live for many years, managing the disease as a chronic condition with periodic monitoring.
Regular follow-up scans and blood work are essential to detect potential recurrence early.
Benefits of Non-Hodgkin Lymphoma Treatment
Offers a high chance of a total cure for many aggressive high-grade types.
Effectively manages symptoms and maintains quality of life for those with slow-growing indolent types.
Provides cutting-edge options like CAR T-cell therapy for patients who have relapsed after standard treatments.
Utilizes targeted antibodies to increase treatment success while minimizing damage to healthy cells.
